

Supplementary Table S2. Representativeness of study participants

Cancer type	B-cell Non-Hodgkin Lymphoma (NHL)
Considerations related to:	
Sex	NHL is more common in men than in women. Between 2015 and 2019, the rate of new cases per 100,000 persons was 23.0 for males and 15.8 for females.
Age	The median age at diagnosis is 67 years, and the median age at death is 76 years.
Race/ethnicity	In the US, the incidence of NHL is highest in Non-Hispanic Whites at 24.7 new cases per 100,000 persons for males and 16.7 new cases per 100,000 persons for females. In the Hispanic population, the rates are 20.2 and 15.3 new cases per 100,000 persons for males and females, respectively. The incidence is lower in the Non-Hispanic Black population, at 17.4 new cases per 100,000 persons for males and 12.4 new cases per 100,000 persons for females.
Geography	In the U.S., NHL is the seventh most common cancer and represents 4.2% of new cancer diagnoses. It is estimated that there will be 80,470 new cases of NHL in the U.S. in 2022 and 20,250 deaths 2022. In California, between 2015 and 2019, the average annual number of cases was 7,721.
Other considerations	In clinical trials evaluating CD19 directed CAR-T cells, the majority of the patients were White with singledigit percentages of Hispanic and Black patients enrolled, which highlights the lack of representation of non-White populations in CAR-T cell therapy trials.
Overall representativeness of this study	The median age of 59 years on our study is slightly lower than the median age of diagnosis of 67, but is consistent with other CAR-T cells therapy trials.
	There is a male predominance in NHL and there were more male patients than female patients enrolled in our study. Three of the patients that screen failed were female.
	The race/ethnicity of our study population was representative of the patient population seen at our institution.